The resynchronization-defibrillation for ambulatory heart failure trial ( RAFT ) study demonstrated that adding cardiac resynchronization therapy ( CRT ) in selected patients requiring de novo implantable cardiac defibrillators ( ICD ) reduced mortality as compared with ICD therapy alone , despite an increase in procedure-related adverse events .